TherapeuticsMD — Third Quarter 2026 Earnings Summary

TherapeuticsMD, Inc. reported net income from continuing operations of $501 thousand, or $0.04 per share, for the third quarter of 2026, an increase from $50 thousand in the same period of 2025. License revenues rose to $1.3 million, driven by a $365 thousand milestone payment from Knight related to IMVEXXY sales for the year ended December 31, 2025. Total operating expenses increased by 5.6% to $1.7 million, primarily due to higher legal and professional fees. As of September 30, 2026, the company held $10.4 million in cash and cash equivalents while continuing to evaluate strategic alternatives such as a potential acquisition or merger.